Drug Trial Radar · NCT05598320
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Mar 3, 2023
Primary completion
Aug 9, 2024
Study completion Aug 13, 2025
Sponsor
- Lead sponsor
- Ascendis Pharma Growth Disorders A/SIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.
Conditions
- Achondroplasia
Interventions
Navepegritide (TransCon CNP)Drug
Once-weekly subcutaneous injection of 100 µg/kg Navepegritide (TransCon CNP)
Placebo for Navepegritide (TransCon CNP)Drug
Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide (TransCon CNP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Growth Velocity (AGV) at Week 52Time frame: At Week 52
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Saint Paul, Minnesota
Ascendis Pharma Investigational Site
Columbia, Missouri
Ascendis Pharma Investigational Site
Houston, Texas
Ascendis Pharma Investigational Site
Madison, Wisconsin
Ascendis Pharma Investigational Site
Parkville, Australia
Ascendis Pharma Investigational Site
Montreal, Canada
Ascendis Pharma Investigational Site
Copenhagen, Denmark
Ascendis Pharma Investigational Site
Dublin, Ireland
Ascendis Pharma Investigational Site
Auckland, New Zealand
Ascendis Pharma Investigational Site
Vitoria-Gasteiz, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.